NovaBay Pharmaceuticals Inc (NBY)

NBY on American Stock Exchange

0.74USD
22 Sep 2014
Price Change (% chg)

$-0.03 (-4.45%)
Prev Close
$0.77
Open
$0.76
Day's High
$0.78
Day's Low
$0.74
Volume
153,715
Avg. Vol
337,995
52-wk High
$2.03
52-wk Low
$0.69

NBY

Chart for NBY

About

NovaBay Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on addressing the unmet therapeutic needs of the global anti-infective market. The Company’s Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a spectrum of activity against bacteria, viruses and fungi. The Company is... (more)

Overall

Beta: 0.45
Market Cap (Mil.): $37.58
Shares Outstanding (Mil.): 50.78
Dividend: --
Yield (%): --

Financials

  NBY Industry Sector
P/E (TTM): -- 144.58 33.70
EPS (TTM): -0.34 -- --
ROI: -134.60 -2.25 17.35
ROE: -176.41 -6.85 18.21
Search Stocks

Competitors

  Price Change
PuriCore plc (PURI.L) 35.50p 0.00
C.R. Bard, Inc. (BCR.N) $147.11 -0.12
Smith & Nephew plc (SN.L) 1,034.16p -34.00
Abbott Laboratories (ABT.N) $43.40 -0.19
GlaxoSmithKline plc (GSK.L) 1,428.50p -15.00
3M Co (MMM.N) $145.71 -0.98
Sanofi SA (SASY.PA) €87.77 -1.10
Pfizer Inc. (PFE.N) $30.18 -0.22
Novartis AG (NOVN.VX) CHF87.85 -0.40
Johnson & Johnson (JNJ.N) $107.88 -0.11

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks